Abstract

The present invention relates to a fluorescently-labeled stem cell line with hepatic stellate cell activation markers, and a method for screening for liver fibrosis-inducing factors or fibrosis-inhibiting factors by using same. A human induced pluripotent stem cell line for screening for liver fibrosis-inducing factors or fibrosis-inhibiting factors, prepared according to the present invention, enables screening for an inducing substance capable of inducing liver fibrosis or a substance capable of inhibiting liver fibrosis in a state in which cells are alive in hepatic stellate cells derived from a pluripotent stem cell line, and thus can be used for imaging-based high-throughput screening (HTS) compound discovery and for discovering liver fibrosis-inducing substances or fibrosis-inhibiting substances by using high-content screening equipment.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases or autoimmune diseases, containing a pyridine compound as an active ingredient. The pyridine compound of the present invention used as the active ingredient of the pharmaceutical composition can significantly inhibit innate immune responses and inflammatory responses by inhibiting the activity of IRAK4 with very high efficacy, and thus can be effectively used for the prevention or treatment of inflammatory diseases or autoimmune diseases.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

A method of producing glucaric acid by electrochemical treatment includes (a) providing a reactor including a first electrode-containing region and a second electrode-containing region separated by an electrolyte membrane, adding a glucose mixture to any one region of the reactor, and adding an electrolyte solution to both regions of the reactor. The method also includes (b) producing glucaric acid by oxidizing glucose by applying a voltage between the first electrode and the second electrode in the reactor subjected to step (a). The electrode in the region to which the glucose mixture is added includes a catalyst containing tantalum.

IPC Classes  ?

• C25B 3/07 - Oxygen containing compounds
• C25B 3/23 - Oxidation
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds

Abstract

The present invention relates to a tin compound, a method for producing same, and a method for forming a thin film using same. The tin compound according to the present invention is thermally stable and has a high volatility and vapor pressure, and thus can be employed as a precursor for a tin-containing thin film to form a high-quality tin-containing thin film. In addition, since the tin compound has excellent extreme ultraviolet (EUV) photosensitivity, a photoresist composition comprising the tin compound can be used to form a fine circuit pattern having high resolution, and thus the tin compound can be highly effectively used in the semiconductor industry.

IPC Classes  ?

• C07F 7/22 - Tin compounds
• C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material from metallo-organic compounds
• C23C 16/40 - Oxides
• C23C 16/34 - Nitrides
• C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• G03F 7/004 - Photosensitive materials
• G03F 7/20 - ExposureApparatus therefor

Abstract

The present invention relates to a method for manufacturing a carbon electrode-based solar cell comprising a perovskite thin film surface-treated through polishing, and a carbon electrode-based solar cell manufactured by the method. According to the present invention, the surface of the perovskite thin film can be smoothed through polishing. Accordingly, the performance and stability of the solar cell are improved by inducing the formation of an effective interface with a hole transport material due to reduced surface roughness. Additionally, the present invention is effective for a carbon electrode-based solar cell, and exhibits improved thermal stability due to the non-use of a metal electrode that is unstable at high temperatures.

IPC Classes  ?

• H10K 71/20 - Changing the shape of the active layer in the devices, e.g. patterning
• H10K 71/60 - Forming conductive regions or layers, e.g. electrodes
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers

Abstract

The present invention relates to a pharmaceutical composition comprising a benzenesulfonamide-substituted heterobicyclic derivative, which is an IRP2 disrupting substance, as an active ingredient for preventing or treating cancer. The present invention can provide a benzenesulfonamide-substituted heterobicyclic derivative compound which interferes the binding of IRP2 to IRE to induce reprogramming of iron metabolism in cancer cells, thereby killing solid cancer, especially colorectal cancer cells.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein is a method for preparing hydrophobic cellulose using Pickering emulsion and hydrophobic cellulose prepared using the same. The hydrophobic cellulose prepared by the method has the effect of improved thermal stability and hydrophobicity.

IPC Classes  ?

• D21C 9/18 - De-watering
• D21C 3/04 - Pulping cellulose-containing materials with acids, acid salts, or acid anhydrides

Abstract

The present invention relates to a method for continuously recovering a styrene monomer from waste polystyrene, and more specifically to a method for continuously recovering a styrene monomer from waste polystyrene, the method comprising mixing with a potassium carbonate (K2CO3) catalyst, and then continuously depolymerizing same, thereby enabling the recovery of a styrene monomer having high yield and high purity.

IPC Classes  ?

• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• B01J 27/232 - Carbonates
• C07C 4/22 - Preparation of hydrocarbons from hydrocarbons containing a larger number of carbon atoms by depolymerisation to the original monomer, e.g. dicyclopentadiene to cyclopentadiene

Abstract

22222); and a method for producing propylene glycol from glycerol through a hydrocracking reaction using the catalyst.

IPC Classes  ?

• B01J 23/78 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with alkali- or alkaline earth metals or beryllium
• B01J 37/16 - Reducing
• C07C 29/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by elimination of hydroxy groups, e.g. by dehydration

Abstract

Disclosed is a means for facilitating, in a method for separating and individually collecting organic acids and alkali salts from organic acid alkali salts, separation/collection of lactic acids and alkali salts via an economic and eco-friendly diffusion analysis method without adding a complicated process such as electrodialysis or electrolysis. During a process of diffusion dialysis of organic acid salts, gaseous components that can release protons are injected into a collection part so that the electroneutrality in solution can be maintained and protons can be transferred to a feed part, thereby facilitating the collection of organic acids. Also, alkali cations that have moved to the collection part may form alkali salts with the gaseous components and be then collected, and a nonsolvent may be used to lower the solubility of the alkali salts for easy collection.

IPC Classes  ?

• B01D 61/24 - Dialysis
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• C07C 51/47 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption

Abstract

Disclosed are a genotoxicity test automation system and a method. The genotoxicity test automation system according to an embodiment of the present invention includes: a design unit that provides a plurality of preset test layouts for each test in response to receiving a test request for a specific test material from a user terminal and implements a complete test cycle design including test items and a test procedure according to one or more test layouts selected by a user through the user terminal; a test unit that receives and stores test data, obtained during a test carried out in accordance with the complete test cycle design, from the user terminal, provides report forms in the form of electronic documents pre-matched with each of the one or more test layouts, receives the test data transmitted in accordance with input items in the report forms, and generates a final report; and a verification unit that carries out a verification procedure for the test results according to preset test guidelines.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
• G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
• G08B 21/18 - Status alarms

Abstract

The present invention relates to a perovskite photoelectric device having high light transmittance and photoelectric conversion efficiency and a method for manufacturing the perovskite photoelectric device, the method comprising: (S1) a charge transport layer complex preparation step of stacking an intermediate layer containing an intermediate layer compound on a charge transport layer; and (S2) a step of stacking a perovskite thin film on the intermediate layer, wherein the intermediate layer compound contains a repeating unit satisfying chemical formula 1 below. (Chemical formula 1) (In chemical formula 1, Z is at least one selected from the group consisting of phosphorus (P), arsenic (As), antimony (Sb), and bismuth (Bi), and n is a positive integer of 1 or greater.)

IPC Classes  ?

• H10K 71/00 - Manufacture or treatment specially adapted for the organic devices covered by this subclass
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10F 10/17 - Photovoltaic cells having only PIN junction potential barriers
• H10F 77/12 - Active materials
• H10K 30/81 - Electrodes
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• C01B 25/42 - Pyrophosphates
• H10F 71/00 - Manufacture or treatment of devices covered by this subclass

Abstract

The present invention relates to a novel indazole derivative, and a use thereof, wherein the indazole derivative has excellent TRIB2 or YAP inhibitory activity, and can be effectively used as a pharmaceutical composition for preventing or treating cancer, narcolepsy, and fasciitis.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention relates to a catalyst for an ammonia decomposition reaction and a hydrogen production method using same. More specifically, the present invention relates to: a catalyst for an ammonia decomposition reaction which, by containing cesium and cerium in a cobalt-molybdenum composite nitride, exhibits excellent catalytic activity in the ammonia decomposition reaction and thus enables an improved ammonia conversion rate, and which shows minimal degradation in activity even after high-temperature and long-duration reactions, offering excellent long-term stability; and a hydrogen production method using the catalyst.

IPC Classes  ?

• B01J 27/24 - Nitrogen compounds
• B01J 37/08 - Heat treatment
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to a series of novel triazolomethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a biodegradable adhesive, a manufacturing method therefor, and an adhesive sheet comprising same, the biodegradable adhesive comprising: epoxidized soybean oil; and two or more kinds of aliphatic dicarboxylic acid compounds obtained by oxidizing waste plastic, wherein the biodegradable adhesive not only exhibits improved adhesive properties and high biodegradability, but also has excellent eco-friendliness due to the preparation thereof using raw materials obtained by recycling waste.

IPC Classes  ?

• C09J 191/00 - Adhesives based on oils, fats or waxesAdhesives based on derivatives thereof
• C09J 7/22 - PlasticsMetallised plastics
• C09J 11/06 - Non-macromolecular additives organic
• C08L 93/04 - Rosin
• C08G 59/32 - Epoxy compounds containing three or more epoxy groups
• C08G 59/42 - Polycarboxylic acidsAnhydrides, halides, or low-molecular-weight esters thereof
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation

Abstract

The present invention relates to a method for manufacturing a carbon electrode-based device and a carbon electrode-based device manufactured by the method. According to the present invention, introducing a solvent treatment process using a fluorosolvent induces densification of a carbon electrode without damaging a hole transport layer or perovskite, and thus an effective interface can be formed between the carbon electrode and the hole transport layer. Accordingly, reduction in porosity results in improved conductivity of the carbon electrode, and interface optimization leads to enhanced device performance. In addition, the present invention is suitable for large-area applications at low cost and is compatible with various processes, such as lamination and hot pressing, which can be applied to carbon electrodes.

IPC Classes  ?

• H10K 71/60 - Forming conductive regions or layers, e.g. electrodes
• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour

Abstract

The present invention relates to an antibacterial polymer composition containing a polymer compound in which a cationic monomer and a fluorine-based acrylic monomer are graft-polymerized in a fluorine-based copolymer. A fluorine-based polymer composition according to the present specification exhibits an antibacterial effect of 99.9% or more, exhibits a contact angle of 150 degrees or greater with respect to a solvent, and thus can be applied to a coating agent exhibiting high air permeability, contamination resistance, and antibacterial effect.

IPC Classes  ?

• C09D 127/16 - Homopolymers or copolymers of vinylidene fluoride
• C09D 5/14 - Paints containing biocides, e.g. fungicides, insecticides or pesticides
• C09D 133/16 - Homopolymers or copolymers of esters containing halogen atoms

Abstract

A sugar composition of the present invention is a formulation containing sugar that can be easily absorbed into plant leaves and stems and immature fruits. When the sugar composition is diluted or dissolved in water and sprayed onto plant leaves and stems and immature fruits, sugar is rapidly absorbed into a plant and translocated like sugar produced through photosynthesis, and thus, the sugar composition can exhibit various effects such as plant growth promotion, fruit fattening, fruit coloring promotion, and increased sugar content in fruits. In addition, since sugar is rapidly absorbed into the inside of leaves after being sprayed onto the leaves, there is the effect in which the concentration of sugar remaining on the surface is rapidly lowered, and thus, the sugar composition can be safety used in the control of pest such as mites and aphids.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 25/06 - Aerosols
• A01N 25/14 - Powders or granules wettable
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01P 15/00 - Biocides for specific purposes not provided for in groups
• A01P 21/00 - Plant growth regulators

Abstract

One embodiment of a carbon dioxide capturing apparatus according to the present invention comprises: an absorption column comprising a carbon dioxide adsorption or carbon dioxide absorption part for adsorbing or absorbing carbon dioxide from an exhaust gas; a regeneration column connected to the absorption column and comprising an adsorbent heating part, which is for heating an adsorbent circulating the inside thereof, and an absorbent heating part which is for heating an absorbent circulating the inside thereof; and the adsorbent or absorbent circulating the absorbent column and the regeneration column to alternately perform adsorption and desorption of carbon dioxide or absorption and desorption of carbon dioxide. The carbon dioxide capturing apparatus is characterized in that: a line is branched from a first dynamic-pressure gas line connecting a line, for carbon dioxide desorbed in the regeneration column, and an absorption column hopper, so as to supply a low density oxygen gas to the absorption column hopper; and a line is branched from a second dynamic-pressure gas line connecting a line, for discharging a carbon dioxide-removed exhaust gas to the outside through the upper end of the absorption column, and a regeneration column hopper, so as to supply a low density oxygen gas to the regeneration column hopper.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/12 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with moving adsorbents with dispersed adsorbents according to the "fluidised technique"
• B01D 53/83 - Solid phase processes with moving reactants
• B01D 53/96 - Regeneration, reactivation or recycling of reactants

Abstract

The present invention relates to a non-oxidative direct conversion reactor for methane and a method for producing C2 hydrocarbon compounds and aromatic compounds using the same. More specifically, it concerns a reactor and method that enable the production of C2 hydrocarbon compounds and aromatic compounds from methane, significantly improving methane consumption while ensuring high yields of C2 hydrocarbon compounds and aromatic compounds even at low reaction temperatures.

IPC Classes  ?

• C07C 2/58 - Catalytic processes
• B01J 8/00 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes
• C07C 9/06 - Ethane
• C07C 11/04 - Ethene
• C07C 11/24 - Acetylene

Abstract

The present invention relates to a method for producing light olefins from waste plastics, the method comprising the steps of: a) pyrolyzing a waste plastic feedstock to generate an oil-containing stream; b) reacting part or all of the oil-containing stream in one or more reactors in the presence of a catalyst; and c) separating and recovering light olefins from the reaction product, wherein, in step b), the catalyst comprises a dehydrogenation catalyst and a cracking catalyst.

IPC Classes  ?

• C10G 11/02 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils characterised by the catalyst used
• C10G 11/05 - Crystalline alumino-silicates, e.g. molecular sieves
• C10G 1/00 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal
• C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste

Abstract

The present invention relates to a method for producing fibrous biomass, including a hydration grinding process and a physical treatment process, the method comprising the steps of: pretreating and grinding herbaceous biomass and supplying same to a hydration extruder; supplying, to a disk refiner, the resulting hydrated biomass extrudate that has undergone hydration grinding by the hydration extruder; and physically treating the hydrated biomass extrudate by controlling the solid-to-liquid ratio of the disk refiner. The fibrous biomass produced by the method is suitable for use as a high-strength reinforcing material in a biodegradable resin composition.

IPC Classes  ?

• D01B 9/00 - Other mechanical treatment of natural fibrous or filamentary material to obtain fibres or filaments
• C08L 101/16 - Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• C08L 97/02 - Lignocellulosic material, e.g. wood, straw or bagasse
• C08L 1/02 - CelluloseModified cellulose
• C08K 7/02 - Fibres or whiskers

Abstract

The present invention relates to a 5-halomethylfurfural production method involving a pretreatment step and, specifically, to a 5-halomethylfurfural production method whereby the yield of halomethylfurfural can be maximized by performing a pretreatment that improves the degree of solubilization of a sugar component before dehydration.

IPC Classes  ?

• C07D 307/50 - Preparation from natural products

Abstract

The present invention relates to a platinum organometallic compound, a method for manufacturing same, a method for manufacturing a thin film using same, and a method for manufacturing a high-performance optical sensor for detecting mid-infrared rays using same.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C23C 16/02 - Pretreatment of the material to be coated
• C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
• C23C 16/448 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for generating reactive gas streams, e.g. by evaporation or sublimation of precursor materials
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber

Abstract

The present invention relates to a novel multi-component organometallic compound, a composition containing same for a solution process, a method for manufacturing a thin film by using same, and a method for manufacturing an optical sensor by using same.

IPC Classes  ?

• C07F 19/00 - Metal compounds according to more than one of main groups
• C23C 18/04 - Pretreatment of the material to be coated
• C23C 18/12 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by thermal decomposition characterised by the deposition of inorganic material other than metallic material
• H10F 71/00 - Manufacture or treatment of devices covered by this subclass
• H10F 77/169 - Thin semiconductor films on metallic or insulating substrates

Abstract

A precursor for preparing an ammonia synthesis catalyst, of the present invention, is prepared according to a specific preparation method, and thus the ratio of a specific peak of 0.4 or greater can be satisfied during X-ray diffraction (XRD) analysis, and thus a quaternary catalyst exhibiting high efficiency can be prepared. The ammonia synthesis catalyst prepared from the precursor can have a high ammonia synthesis rate such that ammonia can be prepared with high efficiency even with a small amount of catalyst.

IPC Classes  ?

• B01J 23/882 - Molybdenum and cobalt
• B01J 23/887 - Molybdenum containing in addition other metals, oxides or hydroxides provided for in groups
• B01J 35/70 - Catalysts, in general, characterised by their form or physical properties characterised by their crystalline properties, e.g. semi-crystalline
• B01J 37/08 - Heat treatment
• B01J 37/03 - PrecipitationCo-precipitation
• C01C 1/04 - Preparation of ammonia by synthesis

Abstract

The present invention relates to a method for producing modified natural oil using an ammonium salt catalyst, and modified natural oil produced by using same. The ammonium salt catalyst, according to the present invention, acts as a homogeneous catalyst during a reaction for producing modified natural oil to cause the reaction to proceed within a short period of time, and after completion of the reaction, a solvent is added to recrystallize and recover the catalyst, thereby allowing for reuse.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 38/68 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended including substantial dissolution or chemical precipitation of a catalyst component in the ultimate reconstitution of the catalyst
• C11C 3/10 - Ester interchange

Abstract

The invention provides compounds of Formula (I): The invention provides compounds of Formula (I): as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

IPC Classes  ?

• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention relates to a method for preparing 5-acetoxymethyl furfural (AMF) from sugar ingredients and, specifically, to a method for preparing 5-acetoxymethyl furfural (AMF) from sugar ingredients by converting XMF into AMF without separation and purification, which remove an extraction solvent from a solution in which an aqueous phase comprising 5-halomethyl furfural (XMF) and an organic phase are mixed, thereby enabling XMF in a crude product form to be directly used without requiring in-process separation and purification equipment.

IPC Classes  ?

• C07D 307/48 - Furfural
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a method for screening for drugs for prevention or treatment of type 2 diabetes mellitus by using an islet organoid and, more specifically, to a method by which drugs that are effective in the prevention or treatment of type 2 diabetes mellitus can be screen for from candidate substances by using an islet organoid, and a platform therefor. The method for screening for drugs for prevention or treatment of type 2 diabetes mellitus by using an islet organoid, according to the present invention, provides a platform and a method using multi-wells of at least 96 wells so as to rapidly screen for new drug candidate substances that are effective in the prevention or treatment of type 2 diabetes mellitus by using an islet organoid having a cell composition and physical structure more similar to those of the actual human body. The screening method according to the present invention enables simultaneous deriving of the results of 1) a hormone stimulation test, 2) an inflammatory stress test, and 3) a cytotoxicity test on candidate substances for treatment of type 2 diabetes mellitus through merely a single experiment.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to a molded catalyst and a manufacturing method therefor and, more specifically, to a manufacturing method for a molded catalyst capable of sufficiently expressing coating strength, improving or maintaining catalytic activity even with a small amount of catalytically active metal, minimizing the use of a catalyst coating solution, and being reusable, thereby reducing the loss of the catalyst coating solution, and to a molded catalyst manufactured by the manufacturing method.

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts

Abstract

The present invention relates to a method for producing a canine atopic dermatitis animal model, a canine atopic dermatitis animal model produced thereby, and a use thereof. According to the present invention, a canine atopic dermatitis animal model is produced by skin stimulation on a dog through epicutaneous sensitization with ovalbumin at a concentration of 1 to 5 mg/ml once daily for 1 to 2 weeks and then with ovalbumin at a concentration of 1 to 5 mg/ml once daily for 2 to 8 weeks. The resulting animal model exhibits clinical symptoms of atopic dermatitis, changes in relevant factors such as increased expression levels of IgE and CCL17, and elevated expression levels of Th2-related cytokines IL-4, IL-31, and IL-13. Therefore, this invention enables the establishment of a standardized animal model for symptoms and Th2 immune responses appearing upon the onset of atopic dermatitis, and the model can be used in clinical studies for screening candidate agents for the prevention, alleviation, or treatment of atopic dermatitis.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• A61K 38/38 - Albumins
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a human lung cell system introduced with a fluorescent reporter for evaluating inhalation toxicity. Using the CRISPR-Cas9 system, a human lung cell line was established in which a fluorescent marker is permanently expressed endogenously at the 3'-terminal portion of the G3BP1 gene, which is one of the representative proteins constituting phase separation phenomena, and after treating the human lung cells with test substances for toxicity evaluation, the formation of phase separation phenomena, specifically stress granules, could be confirmed in real time, thereby providing an effect of simply confirming pulmonary toxicity in real time according to exposure to medicines, chemicals, environmental harmful factors, and biological harmful factors, and thus the present invention can be effectively used for inhalation toxicity evaluation.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention relates to a toxicity evaluation system based on a human pluripotent stem cell model with an introduced fluorescent marker for the real-time monitoring of cytoplasmic phase separation phenomenon, in which a CRISPR-Cas9 system was used to establish human pluripotent stem cells with permanent endogenous expression of a fluorescent marker at the C-terminal of the G3BP1 gene, which is one of the representative proteins involved in phase separation phenomena, and it can be confirmed that the human pluripotent stem cells have no problem with differentiation into three germ layers, and undergo phase separation phenomena, particularly, formation of stress granules, in real time upon treatment with a test substance. Therefore, this system can be effectively used as a technology that enables real-time evaluation of toxicity resulting from exposure to various harmful factors, after differentiating human pluripotent stem cells into various cells and organoids that constitute the human body.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention relates to a compound for inhibiting the activity of UBA6-specific E2 conjugating enzyme 1 (USE1), and a pharmaceutical composition for preventing or treating cancer, comprising same. The compound according to the present invention, which has an aryl substituted basepair and oxycarbonylsulfamate as a basic structure, effectively inhibits the activity of USE1 so as to inhibit tumor growth, and thus can be used in the prevention and/or treatment of various cancers.

IPC Classes  ?

• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
• C07H 19/173 - Purine radicals with 2-deoxyribosyl as the saccharide radical
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 35/00 - Antineoplastic agents
• A23L 33/13 - Nucleic acids or derivatives thereof

Abstract

The present invention relates to a human skin cell system containing a fluorescent reporter for evaluating skin irritation, wherein a CRISPR-Cas9 system was used to establish a human skin cell line in which a fluorescent marker is permanently endogenously expressed in a 3'-terminal region of the G3BP1 gene, which is a representative protein that undergoes the phase separation phenomenon, and phase separation, specifically the formation of stress granules, can be confirmed in real time after the human skin cells are treated with a test material for evaluating skin irritation, and thus the present invention can be effectively used for evaluating skin toxicity due to exposure to various harmful factors (medicines, chemicals, environmental harmful factors, and biological harmful factors).

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present disclosure relates to a gel electrolyte composition including a fluorine-containing copolymer including repeating units represented by following Formula 1 and following Formula 2, lithium salt, and an organic solvent, and a secondary battery including the same.

IPC Classes  ?

• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to a pyrimidine-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. The pyrimidine-2,4-diamine derivative exhibits a high inhibitory ability against EGFR and HER2 mutations, and thus can be advantageously used in the treatment of cancer in which EGFR and HER2 mutations have occurred. In addition, the pyrimidine-2,4-diamine derivative exhibits a significant synergistic effect when administered in combination, and thus may be advantageously used in combination therapy.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

A method of producing a catalyst for synthesizing alkyl acrylate from alkyl lactate and a method of producing alkyl acrylate using the catalyst are disclosed herein. More specifically, a catalyst including zeolite is produced by a method that does not use an organic structure directing agent, and a dehydration reaction of alkyl lactate is promoted using the catalyst, thereby obtaining alkyl acrylate in a yield higher than obtained by conventional methods.

IPC Classes  ?

• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 37/04 - Mixing
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 37/30 - Ion-exchange
• C01B 39/02 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereofDirect preparation thereofPreparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactantsAfter-treatment thereof
• C01B 39/38 - Type ZSM-5
• C07C 67/327 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groupsPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form

Abstract

The present invention relates to an apparatus for manufacturing a water electrolysis membrane and method for manufacturing a water electrolysis membrane using same, and can provide a water electrolysis membrane having excellent physical properties, such as low sheet resistance, low hydrogen permeability, and excellent durability, compared to conventional commercial membranes.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/26 - Polyalkenes
• B01D 71/36 - Polytetrafluoroethene
• B01D 71/66 - Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
• C08J 5/22 - Films, membranes or diaphragms
• C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
• C25B 13/08 - DiaphragmsSpacing elements characterised by the material based on organic materials
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water

Abstract

The present invention relates to a catalyst and a preparation method therefor, wherein the catalyst can convert diesel, which is increasingly likely to be unused, to a basic chemical raw material, and induce a thermal polymerization reaction by combining a strong endothermic reaction of diesel with an olefin reaction of methanol, which is a type of exothermic reaction, to minimize the amount of energy used in a catalytic cracking reaction of diesel. An aspect of the present invention provides a catalyst for use in a reaction for preparing a hard olefin by catalytic cracking of a mixture of diesel and methanol, and is technically characterized in that the catalyst comprises: porous zeolite with pores; and phosphorus supported inside the pores of the porous zeolite and/or on the surface of the porous zeolite, and the catalyst has a retention time of isobutane gas in the pores of 0.400-1.240 min/g.

IPC Classes  ?

• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C10G 11/05 - Crystalline alumino-silicates, e.g. molecular sieves

Abstract

The present invention relates to a quinazoline derivative, a salt thereof, and a pharmaceutical composition comprising same as an active ingredient, which inhibit MASTL activity, and thus can exhibit an effect of preventing or treating cancer and, in particular, can exhibit an effective anticancer effect on cancer in which MASTL is overexpressed, such as breast cancer.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents
• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

The present invention relates to a catalyst for simultaneously producing an alcohol and an acid from a sugar and a method for simultaneously producing an alcohol and an acid from a sugar by using same and, more specifically, to a catalyst that is easily recoverable and enables the stable and simultaneous production of an acid and an alcohol from a sugar under mild reaction conditions with low temperature and low pressure compared with existing reaction conditions, and to a method for simultaneously producing an alcohol and an acid from a sugar by using same.

IPC Classes  ?

• B01J 23/42 - Platinum
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 21/04 - Alumina
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• C07C 51/31 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation of cyclic compounds with ring-splitting
• C07C 59/105 - Polyhydroxy carboxylic acids having five or more carbon atoms, e.g. aldonic acids
• C07C 29/132 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of tumors, containing a novel pyrazolopyrimidine compound or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is administered in combination with other anticancer agents, and thus can be effectively used as a composition for preventing or treating cancer.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an anticancer pharmaceutical compound comprising a novel amide derivative compound as an active ingredient. The compound of the present invention can contribute to cancer immunotherapy by inhibiting a target protein involved in the Trp-Kyn conversion mechanism to induce the death of cancer cells and thus can be used for preventing or treating cancer diseases.

IPC Classes  ?

• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/426 - 1,3-Thiazoles
• A61P 35/00 - Antineoplastic agents
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The present invention relates to a novel imine derivative compound and a use thereof. The compound of the present invention can contribute to cancer immunotherapy by inhibiting a target protein involved in the Trp-Kyn conversion mechanism so as to induce the death of cancer cells, and thus can be used for preventing or treating cancer diseases.

IPC Classes  ?

• C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 35/00 - Antineoplastic agents
• C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Abstract

The present disclosure relates to a real-time chemical screening method using hepatic organoids fluorescently labeled with cytochrome P450 1A1 enzyme. The method for screening an AHR modulator or a hazardous chemical using CYP1A1 fluorescently labelled human pluripotent stem cell line-derived hepatic organoids according to the present disclosure enables the detection of substances that induce CYP1A1 regulation with higher sensitivity than when using the conventional human pluripotent stem cell line-derived hepatocytes by using hepatic organoids that can mimic the human body, and thus can be usefully utilized for early screening of new toxic or carcinogenic compounds while replacing animal testing.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a cobalt-based shaped catalyst for a Fischer-Tropsch synthesis reaction and a method for preparing same and, more specifically, to a method for preparing a cobalt-based shaped catalyst for a Fischer-Tropsch synthesis reaction and to a cobalt-based shaped catalyst for a Fischer-Tropsch synthesis reaction prepared by the preparation method, wherein the catalyst can produce a synthetic liquid fuel having a carbon number of 5 or more without an upgrading process by increasing the activity of the Fischer-Tropsch synthesis reaction while simultaneously promoting an isomerization reaction and a cracking reaction.

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B01J 23/75 - Cobalt
• B01J 29/072 - Iron group metals or copper
• C10G 2/00 - Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon

Abstract

Provided is a carbon dioxide capturing apparatus comprising: a reaction tower including a carbon dioxide adsorption unit or a carbon dioxide absorption unit which adsorbs or absorbs carbon dioxide from exhaust gas; desorption tower connected to the reaction tower and including an adsorbent heating unit for heating an adsorbent circulating inside or an absorbent heating unit for heating an absorbent circulating inside; an adsorbent or absorbent which circulates in the reaction tower and the desorption tower and alternately adsorbs and desorbs carbon dioxide or alternately absorbs and desorbs carbon dioxide; and a heat exchange unit which desorbs carbon dioxide from the adsorbent on which carbon dioxide is adsorbed or the absorbent in which carbon dioxide is absorbed, through heat exchange between the adsorbent on which carbon dioxide is adsorbed and the heated adsorbent, or between the absorbent in which carbon dioxide is absorbed and the heated absorbent, wherein the adsorbent on which carbon dioxide is adsorbed and the heated adsorbent, or the absorbent in which carbon dioxide is absorbed and the heated absorbent are transferred in a co-current flow manner.

IPC Classes  ?

• B01D 53/12 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with moving adsorbents with dispersed adsorbents according to the "fluidised technique"
• B01D 53/62 - Carbon oxides
• B01D 53/83 - Solid phase processes with moving reactants
• B01D 53/96 - Regeneration, reactivation or recycling of reactants

Abstract

The present disclosure relates to a method for producing light olefins from waste plastic, the method comprising the steps of: a) pyrolyzing a waste plastic raw material to produce an oil-containing stream; b) reacting some or all of the oil-containing stream in the presence of a catalyst in at least one circulating fluidized bed reactor; c) separating light olefins from a reaction product and recovering same, wherein the oil-containing stream produced in step a) is introduced into the reactor of step b) without removing olefins and non-hydrocarbon materials.

IPC Classes  ?

• C10G 1/00 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal
• C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste
• C10G 11/02 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils characterised by the catalyst used
• C10G 11/05 - Crystalline alumino-silicates, e.g. molecular sieves
• C10G 11/18 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils with preheated moving solid catalysts according to the "fluidised bed" technique

Abstract

Provided is a process of manufacturing light olefins, which is a fluidized bed catalytic naphtha cracking process having improved economic feasibility and decreased greenhouse gas emissions. The process of manufacturing light olefins according to the present invention has a decreased hot spot occurring when supplying an additional fuel oil and decreased tendency of catalyst deactivation by water, thereby improving economic feasibility of the process and reducing greenhouse gas emissions to allow construction of an environmentally friendly process.

IPC Classes  ?

• B01J 8/18 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles
• B01J 8/26 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles according to "fluidised-bed" technique with two or more fluidised beds, e.g. reactor and regeneration installations
• C10G 11/18 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils with preheated moving solid catalysts according to the "fluidised bed" technique

Abstract

The present disclosure relates to a perovskite optical device including a surface treatment layer, and a manufacturing method therefor. The optical device comprises: a first electrode; a first charge transport layer formed on the first electrode; a perovskite layer formed on the first charge transport layer; a surface treatment layer formed on the perovskite layer; a second charge transport layer formed on the surface treatment layer; and a second electrode formed on the second charge transport layer, wherein the surface treatment layer can be formed through dual surface treatment with a first organic halide and a second organic halide.

IPC Classes  ?

• H10K 30/80 - Constructional details
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 71/60 - Forming conductive regions or layers, e.g. electrodes
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating

Abstract

The present invention relates to a catalyst for converting diesel and kerosene, which are increasingly likely to be not utilized, into basic chemical raw materials, and a method for producing the catalyst, and the catalyst is a catalyst containing a porous zeolite having pores; and phosphorus (P) supported in internal pores of the zeolite and on a surface of the zeolite, wherein the amount of Lewis acid sites in the phosphorus-supported zeolite is 20 to 100 μmol/g, and the catalyst is used for producing a basic chemical raw material through catalytic cracking of a hydrocarbon feed having a boiling point of 150° C. or higher and 550° C. or lower.

IPC Classes  ?

• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 35/51 - Spheres
• B01J 35/64 - Pore diameter
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C10G 11/05 - Crystalline alumino-silicates, e.g. molecular sieves

Abstract

The present invention relates to a composition for improving immune cell activity comprising a TET2 expression inhibitor, and a method for preparing immune cells with improved activity. In addition, the present invention relates to a recombinant vector comprising a nucleic acid encoding a TET2 inhibitor, immune cells with improved activity transduced with the recombinant vector, and a pharmaceutical composition for treating cancer comprising the immune cells.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure relates to a photocurable polymer electrolyte composition and an electrochromic device manufactured by comprising same. More specifically, the photocurable polymer electrolyte composition of the present disclosure includes aromatic polyurethane acrylate, which provides excellent adhesion, thereby improving the interfacial characteristics, optical properties, and response speed of the electrochromic device. The present disclosure further relates to an electrochromic device manufactured by comprising the polymer electrolyte composition.

IPC Classes  ?

• C08F 290/06 - Polymers provided for in subclass
• C08F 2/44 - Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
• C08F 2/50 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents
• C08K 3/105 - Compounds containing metals of Groups 1 to 3 or of Groups 11 to 13 of the Periodic Table
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
• C08G 18/48 - Polyethers
• C08G 18/67 - Unsaturated compounds having active hydrogen
• G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect

Abstract

The present invention relates to a novel glutaminase inhibitor compound and a pharmaceutical composition for the prevention or treatment of cancer or autoimmune diseases, comprising same as an active ingredient. A compound represented by chemical formula 1 disclosed in the present specification exhibits excellent inhibitory activity against glutaminase and has excellent cytotoxicity against cancer cells, and thus is expected to be effective in cancer or autoimmune diseases.

IPC Classes  ?

• C07D 285/12 - 1,3,4-ThiadiazolesHydrogenated 1,3,4-thiadiazoles
• A61K 31/433 - Thiadiazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a compound having autotaxin (ATX) inhibitory activity, a pharmaceutical composition comprising same as an active ingredient, and pharmaceutical uses thereof. The compound according to the present invention exhibits excellent ATX inhibitory activity and can be effectively used for preventing or treating ATX activity-related diseases.

IPC Classes  ?

• C07D 207/448 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to an immunodeficient animal model lacking the MHC gene and a method for producing same. The present invention is based on the finding that the occurrence of graft-versus-host disease is inhibited in mice lacking the B2M gene related to MHC class I, and in humanized mice lacking the B2M and H2-D1 genes related to MHC Class I and the H2-Ab1 gene related to MHC class II, and can thus be effectively used as a model capable of evaluating the efficacy and toxicity of various pharmaceutical products.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12N 5/078 - Cells from blood or from the immune system
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention provides a high-performance gas classification artificial intelligence system and a gas classification method using same. The high-performance gas classification artificial intelligence system according to the present invention comprises at least one gas sensor, and a gas classification server based on an artificial neural network, wherein the gas classification server includes: a reception unit for receiving gas sensing data from the gas sensor; a pre-processing unit for pre-processing the gas sensing data; and a target gas classification unit for classifying the type and concentration of target gas by inputting the pre-processed gas sensing data into a gas classification model based on the artificial neural network, the gas sensing data is a current signal over time, and the pre-processing unit includes a data processing unit for deriving first differential data and second differential data with respect to the time of the current signal, and calculating processed data by using the first differential data and the second differential data.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G06N 3/09 - Supervised learning

Abstract

This disclosure provides compounds of Formula (I) This disclosure provides compounds of Formula (I) This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

IPC Classes  ?

• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 31/14 - Antivirals for RNA viruses
• C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Abstract

An eco-friendly quarantine composition has a function of killing phospholipid enveloped viruses, The eco-friendly quarantine composition includes: 10 to 40 wt. % of polyoxyethylene lauryl ether, 0.01 to 10 wt. % of polyoxyethylene 2-ethylhexyl ether, 0.01 to 10 wt. % of polyoxyethylene polyoxypropylene alkyl ether, and a balance of solvent, based on the total 100 wt. % of the composition. The eco-friendly quarantine composition may have 100% of SARS-CoV-2 virus removal rate in 1 minute and an effect of killing 100% of highly pathogenic avian influenza virus in 1 to 10 minutes. The composition has low cytotoxicity such that IC50 value (%) for human epithelial keratinocyte cells (HaCaT), human bronchial epithelial cells (BEAS-2B), and human monocyte cells (THP-1) is in a range of 0.003 to 0.0045, and effects of having antibacterial activity against non-pathogenic strains, and pathogenic strains.

IPC Classes  ?

• A01N 31/02 - Acyclic compounds
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The present application relates to: a novel isosorbide-based diepoxide compound, a salt thereof, a solvate thereof, and a solvate of the salt thereof; a composition comprising same; use thereof; and a method for preparing same. The novel isosorbide-based diepoxide compound of the present application can be used as a monomer for manufacturing bioplastics, and thus is highly applicable as an eco-friendly material. In addition, the preparation method of the present application enables the synthesis of isosorbide-based diepoxide compounds with high efficiency, and thus can be provided as a useful method for providing isosorbide monomers for manufacturing bioplastics.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems

Abstract

An aspect of the present invention is to provide a fluorine-based polymer showing a significantly low dielectric constant of less than 1.8 and a fluorine-based polymer composition including the same. The fluorine-based polymer provided in an aspect of the present invention shows a very low dielectric constant, wherein the polymer is not only a pollution-reducing material generating no harmful substance, but may also be utilized as a coating material in various fields due to high adhesiveness. Furthermore, a polymer film employing the polymer as a material has a volume resistance of about 5.8×1015 Ohmcm, showing an excellent resistance value as an insulating material.

IPC Classes  ?

• C08F 220/14 - Methyl esters
• C08F 220/22 - Esters containing halogen
• C08J 5/18 - Manufacture of films or sheets

Abstract

The present invention relates to a microfluidic device capable of simulating tissues or organs using cells.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to a catalyst for dehydrogenation of glycerol and to a catalyst for dehydrogenation of glycerol, which includes a group 10 element on the periodic table as a catalytically active component and a composite metal oxide composed of zirconium (Zr) and cerium (Ce) as a catalyst support, and a manufacturing method thereof.

IPC Classes  ?

• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C07C 51/295 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with inorganic bases, e.g. by alkali fusion
• C07C 59/08 - Lactic acid

Abstract

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

The present invention relates to a catalyst for producing a synthesis gas by a reforming reaction of a reducing gas using carbon dioxide, and more specifically to a catalyst for producing a synthesis gas, by which, when a composite catalyst comprising nickel-cobalt, used for reforming reducing gas using carbon dioxide, is newly configured and used in a reforming reaction, excellent catalytic activity and stability are achieved, and an excellent conversion rate of a carbon-based reducing gas is gained.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 32/40 - Carbon monoxide

Abstract

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

The present invention relates to a catalyst support for synthesis gas production, and a catalyst using same. More specifically, a catalyst support used for supporting an active component in a catalyst that is used in synthesis gas production using a reforming reaction in which various reducing agents are used has specific physical properties. Therefore, the present invention relates to a catalyst support and a catalyst prepared using same, the catalyst support being developed such that, if a specific active component of a catalyst is immersed therein and the catalyst is applied to synthesis gas production using a reforming reaction, an excellent catalytic activity effect can be exhibited.

IPC Classes  ?

• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/31 - Density
• B01J 35/61 - Surface area
• B01J 35/50 - Catalysts, in general, characterised by their form or physical properties characterised by their shape or configuration
• B01J 23/755 - Nickel
• B01J 23/75 - Cobalt
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 32/40 - Carbon monoxide

Abstract

scn1labscn1labscn1labscn1lab gene mutation, of the present invention, exhibits characteristics such as seizure-like behavior, color preference, electroencephalogram characteristics, abnormal expression of specific transcripts, neurotransmitter imbalance and the like, and thus can be effectively used for screening for drugs for treatment of seizure-associated diseases such as epilepsy.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a porous support used for the impregnation of a solid polymer electrolyte, a secondary battery comprising same, and a manufacturing method therefor. More specifically, the present invention relates to a porous support used for the impregnation of a solid polymer electrolyte, a secondary battery comprising same, and a manufacturing method therefor, the porous support being capable of utilizing a roll-to-roll process to which in-situ crosslinking is applied.

IPC Classes  ?

• C08J 9/42 - Impregnation with macromolecular compounds
• C08J 9/36 - After-treatment
• C08J 5/22 - Films, membranes or diaphragms
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
• H01M 10/052 - Li-accumulators
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy

Abstract

The present invention relates to a biomarker composition for evaluating drug toxicity of liver organoids, a kit for evaluating drug toxicity of liver organoids, and a method for evaluating drug toxicity of liver organoids. The use of amino acids, which are low molecular metabolites capable of securing measurement reliability, as an index material, allow for the intuitive and reliable measurement for evaluating toxicity of liver organoids, and the measurement of the amino acids in a culture medium, rather than the liver organoid cells themselves, makes it easy to secure a sample and possible to track and observe continuous cell changes. According to the present invention, it is possible to evaluate whether drug-induced liver injury is expressed or not, and not only measurement values of four kinds of amino acid residues, but also ratios between the amino acids can be utilized, so that various approaches can be made according to an applicable measurement method, and the present invention can be utilized even when perfect correction (normalization) such as actual sample usage is impossible.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to: a fluorene-based polymer included in a hole transport layer of a quantum dot light-emitting diode (QD-LED); and a QD-LED comprising same. As fluorine is introduced into the fluorene-based polymer, a HOMO energy level of the hole transport layer is lowered. Therefore, when the fluorine-introduced fluorene-based polymer is included in the hole transport layer, hole injection into an emission layer is improved, and thus performance of the QD-LED may be improved.

IPC Classes  ?

• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• H10K 50/15 - Hole transporting layers
• H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots

Abstract

According to the present disclosure, by forming normal pressure conditions in a reaction system through application of a reflux system to an aqueous phase in the presence of sulfuric acid and an inorganic salt in the dehydration reaction of biomass-derived sugar components in an open system, there is no need to include a high-pressure vessel required in a conventional 5-halomethylfurfural production process, there is no risk of safety accidents, including the explosion of a high-pressure vessel and the leakage of strong acid gas, and there is a remarkable effect in that yield is improved three-fold or more compared to the case of using a conventionally used acid catalyst under the normal pressure conditions.

IPC Classes  ?

• C07D 307/48 - Furfural

Abstract

The present invention pertains to: an ethylene oligomerization catalyst containing a ligand compound; a catalyst composition employing same; and a method for producing an ethylene oligomer by using same. The catalyst exhibits excellent selectivity to oligomers and selectivity to 1-hexane, thus making it possible to mass-produce 1-hexane, which is an industrially useful chemical raw material, with high purity.

IPC Classes  ?

• C08F 4/78 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from refractory metals selected from chromium, molybdenum, or tungsten
• C08F 110/02 - Ethene

Abstract

The present invention relates to a PBRM1 gene marker for predicting the efficacy of an immune checkpoint inhibitor and use thereof. The E27 selective splicing of a PBRM1 gene, of the present invention, is inversely correlated with the expression level of a RBFOX2 protein, and cancer patients including E27 in the PBRM1 gene have low efficacy of an immune checkpoint inhibitor, while cancer patients excluding E27 have enhanced efficacy of an immune checkpoint inhibitor, thus increasing the survival rate when the immune checkpoint inhibitor is prescribed. Therefore, it is expected that the PBRM1 gene marker can be effectively used in predicting the efficacy of an immune checkpoint inhibitor.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a cell scaffold for producing cultured meat, a production method therefor, and a method for producing cultured meat using same. More specifically, the present invention relates to a cell scaffold for producing cultured meat, a production method therefor, and a method for producing cultured meat using same, wherein the cell scaffold is capable of adjusting the contents of muscle tissues and adipose tissues at a desired ratio by reversible physicochemical bonding using a self-healing hydrogel capable of self-healing at a temperature and in a pH range at which cells can be cultured.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

The present invention relates to a method for recycling mixed polymers comprising a polymer having an urethane functional group and/or a polymer having an amide functional group, in which, in recycling mixed polymers comprising a polymer having an urethane functional group and/or a polymer having an amide functional group, by sequentially or simultaneously bringing, into contact with the mixed polymers, a first compound including at least one aromatic compound having one or more alkoxy functional groups and a second compound including at least one compound having one or more alcohol functional groups, the polymer having an urethane functional group in a composite polymer is selectively dissolved, filtered, and separated, and thus the separated polymer having an urethane functional group can be separately depolymerized.

IPC Classes  ?

• C08J 11/08 - Recovery or working-up of waste materials of polymers without chemical reactions using selective solvents for polymer components
• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material

Abstract

22222 hydrocarbon compounds and aromatic compounds, and an improvement in catalyst regeneration efficiency can be attained, leading to improved economic efficiency.

IPC Classes  ?

• C07C 2/58 - Catalytic processes
• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen
• C07C 9/06 - Ethane
• C07C 11/04 - Ethene
• C07C 11/24 - Acetylene
• C07C 15/04 - Benzene
• C07C 15/06 - Toluene
• C07C 15/24 - Polycyclic condensed hydrocarbons containing two rings

Abstract

The present invention relates to a oxygen-free direct conversion of methane reactor and a method for producing ethylene using the same. More specifically, the invention provides a oxygen-free direct conversion of methane reactor and a method for producing ethylene from methane, wherein the reactor is selectively heated to save energy, prevent overheating with high responsiveness, and minimize coke formation, thereby achieving high methane conversion rate and high ethylene yield at a high reaction rate. The method also allows for the production of ethylene and aromatic compounds.

IPC Classes  ?

• B01J 19/24 - Stationary reactors without moving elements inside
• B01J 23/44 - Palladium
• B01J 23/50 - Silver
• B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen

Abstract

The present invention relates to: a recombinant polypeptide comprising a bromodomain variant; a chimeric antigen receptor comprising the bromodomain variant in an intracellular signaling domain; a gene construct comprising a nucleotide sequence encoding the recombinant polypeptide or the chimeric antigen receptor; a cell or an immune cell, each expressing the recombinant polypeptide or the chimeric antigen receptor; a pharmaceutical composition for the prevention or treatment of cancer, comprising the immune cell; a composition for degrading the recombinant polypeptide or chimeric antigen receptor of the immune cell, the composition comprising a PROTAC compound as an active ingredient; and a kit for the prevention or treatment of cancer, comprising the pharmaceutical composition and the PROTAC compound.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 9/10 - Transferases (2.)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are a plasmid comprising dxCas9 and a CRP derivative for controlling the expression of a target gene, a recombinant strain transformed with the plasmid, a preparation method therefor, a target gene control system, and a method for controlling the expression of a target gene, wherein the plasmid, recombinant strain, and expression control system according to the present invention can improve the production of high-value-added substances by construction of a system for simultaneously and multiply controlling the expression of target genes.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided is a secondary battery electrode, which includes a highly adhesive electron conductive layer coupled to an electrode assembly, so as to have improved physical and electrochemical performances. One embodiment of the present invention provides a secondary battery electrode, which includes an electrode assembly and a highly adhesive electron conductive layer coupled to the electrode assembly, wherein the highly adhesive electron conductive layer comprises a substrate and a poly (ethylenedioxythiophene): poly (styrenesulfonate) (PEDOT:PSS).

IPC Classes  ?

• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/04 - Processes of manufacture in general
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to a composite coating film, which has transparency, a self-cleaning function, antibacterial properties, and excellent moisture and oxygen barrier properties. The film comprises: a film substrate; and at least two barrier layers consisting of cellulose-based nanofibers and chitin-based nanofibers substituted with guanidine, which are stacked layer by layer on the film substrate. In addition, the film comprises, on the other side thereof, a self-cleaning porous nano-coating layer in which chitin-based nanofibers substituted with guanidine and inorganic particle layers are alternately stacked layer by layer in two or more layers, wherein the coating layer also comprises an essential oil. The composite coating film provides excellent transparency, oxygen and moisture permeability, and antibacterial effects.

IPC Classes  ?

• C08J 7/04 - Coating
• C08J 7/06 - Coating with compositions not containing macromolecular substances
• C08J 7/054 - Forming anti-misting or drip-proofing coatings
• C08J 5/18 - Manufacture of films or sheets
• C08K 3/36 - Silica
• C09D 101/02 - CelluloseModified cellulose
• C09D 105/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C09D 5/16 - Anti-fouling paintsUnderwater paints
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• B65D 65/42 - Applications of coated or impregnated materials

Abstract

The present invention relates to a nonoxidative methane direct converting reactor and a preparation method of ethylene and aromatic compound using the same and, more specifically, to a nonoxidative methane direct converting reactor and a preparation method of ethylene and aromatic compound using the same, wherein the reactor maximizes a catalytic reaction rate, minimizes cokes production, and provides a high conversion rate of methane and a high yield of ethylene and an aromatic compound even at a low hydrogen supply ratio in the production of ethylene and an aromatic compound from methane.

IPC Classes  ?

• B01J 19/02 - Apparatus characterised by being constructed of material selected for its chemically-resistant properties
• B01J 19/24 - Stationary reactors without moving elements inside
• C07C 2/74 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition with simultaneous hydrogenation

Abstract

The present invention relates to a polymer compound, and an organic photodiode and an X-ray detector comprising same, and relates to: a novel polymer compound having excellent visible light and near-infrared absorption capacity, and being capable of effectively reducing dark current of a device when applied to a photoactive layer of an organic photodiode, thereby significantly improving detection efficiency of visible light and near-infrared; and an organic photodiode and an X-ray detector comprising same.

IPC Classes  ?

• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• H10K 85/10 - Organic polymers or oligomers
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

The present invention relates to a silver nano-zinc oxide composite nanostructure for amplifying a fluorescence signal of a gene probe labeled with fluorescence, to a method for manufacturing same, and to a method for detecting a fluorescence signal and, more specifically, to a silver nano-zinc oxide nanowire in which a nanowire is grown on a substrate, silver nanoparticles formed on the nanowire and a gene probe labeled with fluorescence are comprised, and a distance, at which a metal fluorescence signal can be amplified, between the silver nanoparticles formed on the nanowire and fluorescent molecules of the gene probe is maintained so that the fluorescence signal is amplified. The silver nano-zinc oxide nanowire of the present invention has improved detection sensitivity, thereby enabling more accurate diagnosis.

IPC Classes  ?

• C12Q 1/682 - Signal amplification

Abstract

The present invention relates to: a triazole compound having a novel ring structure; a method for preparing same; and a use thereof. The triazole compound having a novel ring structure according to the present invention exhibits an excellent ability to inhibit ASK1 and inhibits the apoptosis of neurons, and thus can be used for preventing or treating ASK1-related diseases including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

2222 in an eco-friendly manner through simple and easy manipulation of SOEC operating conditions.

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• C25B 13/07 - DiaphragmsSpacing elements characterised by the material based on inorganic materials based on ceramics
• C25B 9/65 - Means for supplying currentElectrode connectionsElectric inter-cell connections
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 11/051 - Electrodes formed of electrocatalysts on a substrate or carrier

Abstract

A polymer electrolyte composition according to the present disclosure has remarkably excellent yellowing resistance and high adhesive strength, and thus an electrochromic device manufactured by comprising same not only has excellent optical and mechanical durability, but also has a large difference in transmittance between a coloration state and a bleaching state. In addition, the electrochromic device is excellent in coloration and bleaching speeds, and thus can be usefully used as a smart window.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/62 - Polymers of compounds having carbon-to-carbon double bonds
• C08G 18/32 - Polyhydroxy compoundsPolyaminesHydroxy amines
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
• C08K 3/105 - Compounds containing metals of Groups 1 to 3 or of Groups 11 to 13 of the Periodic Table
• C08F 220/12 - Esters of monohydric alcohols or phenols
• C08F 220/06 - Acrylic acidMethacrylic acidMetal salts or ammonium salts thereof
• C08F 220/20 - Esters of polyhydric alcohols or phenols
• G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material

Abstract

A lithium sulfide preparation method, according to exemplary embodiments, enables the preparation of a lithium salt-containing superabsorbent polymer by reacting a lithium-sulfur-containing compound solution with a superabsorbent polymer having an absorption rate of 50 g/g to 800 g/g. The lithium salt-containing superabsorbent polymer may be sintered to form lithium sulfide. Accordingly, the stability and economic efficiency of a lithium sulfide production process may be improved, and an eco-friendly process enabling the mass production of lithium sulfide at a low cost may be ensured.

IPC Classes  ?

• C01B 17/22 - Alkali metal sulfides or polysulfides
• H01M 10/0562 - Solid materials
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to: a catalyst for converting diesel and kerosene, which are increasingly underutilized, into basic chemical feedstock; and a method for producing the catalyst. The catalyst comprises: a porous zeolite; and phosphorus (P) supported in inner pores and on the surface of the zeolite, wherein the amount of Lewis acid sites in the phosphorus-supporting zeolite is 20 to 100 μmol/g, and basic chemical feedstock are produced through catalytic cracking of hydrocarbon feedstock having a boiling point of 150 °C to 550 °C.

IPC Classes  ?

• B01J 29/83 - Aluminophosphates [APO compounds]
• C07C 7/148 - Purification, separation or stabilisation of hydrocarbonsUse of additives by treatment giving rise to a chemical modification of at least one compound
• C07C 11/02 - Alkenes
• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 29/08 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 29/18 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment

Abstract

The present disclosure relates to a method of polymerizing a polymer having an ester functional group, a catalyst for use in the method, and a composition for use in the method. More specifically, proposed is a method of depolymerizing a polymer having an ester functional group by using potassium carbonate (K2CO3) as a depolymerization catalyst and an alcohol and a polar aprotic solvent as solvents. In addition, a composition for depolymerizing a polymer having an ester functional group is proposed.

IPC Classes  ?

• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material

Abstract

The present invention provides a composition for promoting NK cell proliferation or improving cell lysis activity of NK cells, comprising, as an active ingredient, feeder cells in which membrane bound interleukin-13 (mbIL-13) or membrane bound interleukin-2 (mbIL-2) is expressed on a cell membrane. The composition of the present invention expresses mbIL-13 or mbIL-2 on the cell membrane of the feeder cells, thereby having excellent effects of promoting the NK cell proliferation and inducing improvement of cell lysis activity of NK cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/54 - Interleukins [IL]
• A61K 35/13 - Tumour cells, irrespective of tissue of origin
• A61K 38/20 - Interleukins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a semiconductor device and a semiconductor material, and more specifically, to an organic semiconductor thin film transistor having a vertical structure, a fusion device of an optical semiconductor material, and a method of manufacturing the same, provides a vertical organic transistor including a substrate, a first electrode layer formed on the substrate, a lower charge transport layer formed on the first electrode layer, a photosensitive layer formed on the lower charge transport layer, an upper charge transport layer formed on the photosensitive layer, a second electrode layer including a base electrode formed on the upper charge transport layer, a plurality of pinholes formed in the base electrode and configured to provide a movement path of charges, and a metal oxide layer surrounding a surface of the base electrode and the pinholes, an organic active layer formed on the second electrode layer, and a third electrode layer formed on the organic active layer.

IPC Classes  ?

• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers

Abstract

The present invention provides a polyamic acid aqueous solution composition capable of polymerizing polyamic acid in water rather than in an organic solvent, as well as achieving a high imidization rate during low-temperature curing.

IPC Classes  ?

• C08G 69/32 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids from aromatic diamines and aromatic dicarboxylic acids with both amino and carboxylic groups aromatically bound
• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media